Bofanglutide
Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects
Gan & Lee Pharmaceuticals · Phase 3 · Recruiting · Enrollment 420
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| GZR18 Dose Level 1 | n/r | n/r | n/r | n/r |
| GZR18 Dose Level 2 | n/r | n/r | n/r | n/r |
| Semaglutide(Wegovy® )2.4 mg | n/r | n/r | n/r | n/r |
Not shown
- GZR18 Dose Level 1: endpoint not reported
- GZR18 Dose Level 2: endpoint not reported
- Semaglutide(Wegovy® )2.4 mg: endpoint not reported